BioCryst Pharmaceuticals Receives Market Perform Rating from JMP Securities (BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “market perform” rating restated by analysts at JMP Securities in a research report issued to clients and investors on Monday, StockRatingsNetwork.com reports.
The analysts wrote, “BCRX provided an update on data flow from its HAE program, including data presentations on kallikrein inhibitor, BCX4161, at AAAAI in late February/early March and data from the 28-day proof-of-concept study in 1H14, which we view as a key value driver for the company. BioCryst has also profiled its second generation kallikrein inhibitors, which have the expected benefits of better bio-availability (at least 5x BCX4161) and selectivity (at least 4x more selective against tissue factor VII). We anticipate that one of these compounds will move into human development in 1H15. BioCryst is also planning to leverage its drug discovery efforts into a second orphan disease in 2H14. We recommend shares of BioCryst into potentially transformative Phase 2a data.”
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 4.27% on Monday, hitting $10.51. The stock had a trading volume of 2,073,329 shares. BioCryst Pharmaceuticals has a 52-week low of $1.12 and a 52-week high of $10.87. The stock has a 50-day moving average of $7.15 and a 200-day moving average of $5.87. The company’s market cap is $621.0 million.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Tuesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). The company had revenue of $2.40 million for the quarter, compared to the consensus estimate of $2.01 million. During the same quarter in the prior year, the company posted ($0.19) earnings per share. The company’s quarterly revenue was down 58.8% on a year-over-year basis. On average, analysts predict that BioCryst Pharmaceuticals will post $-0.53 earnings per share for the current fiscal year.
BCRX has been the subject of a number of other recent research reports. Analysts at Thomson Reuters/Verus downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, December 24th. Separately, analysts at MLV Capital raised their price target on shares of BioCryst Pharmaceuticals from $6.50 to $9.00 in a research note to investors on Thursday, December 19th. They now have a “buy” rating on the stock. Finally, analysts at Merrill Lynch upgraded shares of BioCryst Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and an average price target of $9.00.
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.